biostudies-literatureTamari RNCI NIH HHS3993-4002https://www.ebi.ac.uk/biostudies/studies/S-EPMC10410129biostudies-literatureUnknown7(15)To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the Center for International Blood and Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients who received transplantation in Europe (the European Bone Marrow Transplant [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98-1.96), and HLA-matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with an increased hazard of death and were assigned 1 point. HemoglobiBlood advancesA simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.PMC10410129U24 CA076518Ganguly SAgrawal VYared JAPu JJGrunwald MRGale RPBattiwalla MBeitinjaneh ANathan SEstrada-Merly NGiralt STamari RCutler CMarks DIBredeson CDeFilipp ZDiaz MABashey AVerdonck LFGergis UAbid MBNakamura RSavani BNJain TMcLornan DPHashmi SScott BLKharfan-Dabaja MAOran BCzerw TNishihori TYakoub-Agha ILitzow MRLiesveld JUlrike Bacher VRizzieri DAli HAljurf MHildebrandt GCGupta VLazarus HMvan der Poel MPawarode ASaber WHernandez-Boluda JCSeo SAhn KWSolh MMKindwall-Keller TPalmer JWirk BfalseA simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the Center for International Blood and Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients who received transplantation in Europe (the European Bone Marrow Transplant [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98-1.96), and HLA-matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with an increased hazard of death and were assigned 1 point. Hemoglobi2023-01-01T00:00:00Z2023 Aug2025-04-05T00:22:58.734Z2025-04-05T00:22:58.734ZS-EPMC104101293713430610.1182/bloodadvances.2023009886